{
  "id": 11454798,
  "title": "Teva Reports New Efficacy, Safety Data For Ecopipam In Pediatric Tourette Syndrome",
  "url": "https://urgent.news/2026/10/02/teva-reports-new-efficacy-safety-data-for-ecopipam-in-pediatric",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-02T13:16:25.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/teva-reports-new-efficacy-safety-data-ecopipam-pediatric-tourette-syndrome"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA) presented new efficacy and safety data for ecopipam, an investigational, first-in-class selective dopamine D1 receptor antagonist being developed for pediatric patients with Tourette syndrome.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}